Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Evotec

Biotech & Life Sciences · Hamburg, Germany · Founded 1993 · IPO 2012 Unicorn

Drug discovery and development for pharma and biotech

Valuation
$1.07B
Market cap · May/2026
Revenue
$867M
Latest reported FY
EBITDA
$37M
Latest reported FY

Investors

5 investors on Evotec's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 5 investors entered at this stage
Max Planck Institute for the Structure and Dynamics of Matter
3i Group
Max Planck Innovation
Max Planck Society
Gilde Healthcare

Global footprint

Where Evotec has talent and traffic

AI talent share
2.0% of workforce is AI talent
(97 of 4,847 staff)
Core AI330.68%
Other AI641.32%
Non-AI workforce4,75098%
Workforce by country
25 countries with
team presence
🇩🇪 Germany27.9%
🇫🇷 France27.5%
🇮🇹 Italy19.3%
🇬🇧 United Kingdom18.3%
🇺🇸 United States4.8%
Top 5 of 25 shown
Web traffic by country
80K monthly visits
across markets
🇺🇸 United States19.9%
🇩🇪 Germany12.3%
🇬🇧 United Kingdom7.6%
🇫🇷 France6.5%
🇮🇹 Italy5.6%
Top 5 markets shown

Patent intelligence

$42M patent portfolio · 56 active families

Estimated portfolio value
$42M
4.0% of market cap · 18.4× smaller than top peer BioNTech ($780M)
56 active patent families
Where Evotec innovates Molecular biologyDiseasePhysicsDisease injuryDisease patient

Where Evotec concentrates vs peers

Each axis is a top-10 topic across Evotec and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Evotec's 38 investments and acquisitions.

Every disclosed deal where Evotec appeared as a backer or acquirer, 2000–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

38 deals across Evotec's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Evotec deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Evotec's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        38 of 38 deals

        Market sentiment

        What the market is saying about Evotec

        An AI-synthesized read of the highest-engagement posts about Evotec on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Evotec on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.